Pediatric ARDS phenotypes in critical COVID-19: implications for therapies and outcomes.

Jesús Domínguez-Rojas<sup>1,2,3</sup> (ORCID 0000-0001-6141-6622), Yesica Luna-Delgado<sup>4</sup>, Patrick Caqui-Vilca<sup>5</sup>, Carlos Martel-Ramírez<sup>5</sup>, Miguel Quispe-Chipana<sup>5</sup>, Mario Cruz-Arpi<sup>5</sup>, Noé Atamari-Anahui<sup>6</sup>, Cleotilde Mireya Muñoz Ramírez<sup>7</sup>, Gaudi Quispe Flores<sup>1</sup>, Mariela Tello-Pezo<sup>8</sup>, Pablo Cruces<sup>3,9,10</sup> (ORCID 0000-0001-9337-1254), Pablo Vásquez-Hoyos<sup>3,11,12</sup> (ORCID 0000-0002-4892-5032), Franco Díaz<sup>3,9,13</sup> (ORCID 0000-0003-4763-074X)

- 1. Hospital Nacional Edgardo Rebagliati Martins, Departamento de Pediatría, Lima, Perú.
- Hospital Nacional de Emergencias de Villa El Salvador. División de Cuidados Críticos Pediátricos,
  Lima, Perú.
- 3. LARed Network, Red Colaborativa Pediátrica de Latinoamérica.
- 4. Hospital Nacional Regional de Cusco, División de Cuidados Críticos Pediátricos, Perú.
- 5. Hospital Nacional Hipólito Unanue, Lima, División de Cuidados Críticos Pediátricos, Lima, Perú.
- Universidad San Ignacio de Loyola, Vicerrectorado de Investigación, Unidad de Investigación para la Generación y Síntesis de Evidencias en Salud, Lima, Perú.
- 7. Instituto Nacional de Pediatría, División de Cuidados Críticos Pediátricos, Ciudad de México.
- 8. Instituto Nacional de Salud del Niño San Borja. Departamento de Pediatría, Lima, Perú.
- 9. Hospital El Carmen de Maipú, Unidad de Cuidados Intensivos Pediátricos, Maipú, Chile.
- 10. Facultad de Ciencias de la Vida, Universidad Andres Bello, Santiago Chile.
- 11. Departamento de Pediatría, Fundación Universitaria de Ciencias de la Salud, Bogotá, Colombia.
- 12. Departamento de Pediatría, Universidad Nacional de Colombia, Bogotá, Colombia.
- 13. Escuela de Medicina, Universidad Finis Terrae, Santiago, Chile.

**Correspondence**: Jesús Angel Domínguez Rojas. Departamento de Pediatria y Paciente Crítico Pediátrico, Hospital Edgardo Rebagliati Martins, jesusdominguez24@gmail.com

Pediatric Acute Respiratory Disease Syndrome phenotypes in critical COVID-19: implications for

therapies and outcomes.

Purpose: to describe lung mechanics in Pediatric Acute Respiratory Disease Syndrome (PARDS) associated

with COVID-19. We hypothesize two phenotypes according to respiratory system mechanics and clinical

diagnosis.

Methods: a concurrent multicenter observational study was performed, analyzing clinical variables and

pulmonary mechanics of PARDS associated with COVID-19 in 4 Pediatric intensive care units (PICUs) of Perú.

Subgroup analysis included PARDS associated with multisystem inflammatory syndrome in children (MIS-C),

MIS-PARDS, and PARDS with COVID-19 primary respiratory infection, C-PARDS. In addition, receiver

operator curve analysis (ROC) for mortality was performed.

Results: 30 patients were included. Age was 7.5(4-11) years, 60% male, and mortality 23%. 47% corresponded

to MIS-PARDS and 53% to C-PARDS phenotypes. C-PARDS had positive RT-PCR in 67% and MIS-PARDS

none (p<0.001). C-PARDS group had more profound hypoxemia (P/Fratio<100, 86% vs38%,p<0.01) and higher

driving-pressure (DP) [14(10-22)vs10(10-12)cmH<sub>2</sub>O], and lower compliance of the respiratory system

 $(C_{RS})[0.5(0.3-0.6)vs 0.7(0.6-0.8)ml/kg/cmH<sub>2</sub>O]$  compared to MIS-PARDS (all p<0.05). ROC-analysis for

mortality showed that DP had the best performance [AUC 0.91(95%CI0.81-1.00), with the best cut-point of 15

cmH<sub>2</sub>O (100% sensitivity and 87% of specificity). Mortality in C-PARDS was 38% and 7% in MIS-

PARDS(p=0.09). MV free-days were 12(0-23) in C-PARDS and 23(21-25) in MIS-PARDS(p=0.02)

Conclusion: critical pediatric COVID-19 is heterogeneous in children. COVID-19 PARDS had two phenotypes

with distinctive pulmonary mechanics features. Characteristics of C-PARDS are like a classic primary PARDS,

while a decoupling between compliance and hypoxemia was more frequent in MIS-PARDS. In addition, C-

PARDS had fewer MV free-days. DP ≥ 15 cmH2O had the best performance of the quasi-static calculations to

discriminate for mortality. Standardized pulmonary mechanics measurements in PARDS might reveal essential

information to tailor the ventilatory strategy in pediatric critical COVID-19.

2

**Keywords**: PARDS, COVID-19, MIS-C, Pulmonary mechanics, Driving pressure.

### Pediatric ARDS phenotypes in critical COVID-19: implications for therapies and outcomes.

#### "Take-home message"

- PARDS associated with COVID-19 have two different phenotypes based on clinical diagnosis and pulmonary mechanics.
- C-PARDS group was characterized as a classic moderate to severe primary ARDS. A decoupling between compliance and hypoxemia was more frequent in MIS-PARDS. Regarding outcomes, C-PARDS had less
   VFD and a trend toward higher mortality.
- Data from the quasi-static calculations were associated with mortality; DP≥ 15 cmH2O was the best discriminator.
- Standardized pulmonary mechanics measurements in PARDS might reveal essential information to tailor the ventilatory strategy, characterizing different phenotypes and parameters associated with outcomes.

## Tweet

Lung mechanics help to differentiate two different phenotypes in PARDS associated with COVID-19. C-PARDS associated with respiratory infection, and MIS-PARDS, associated with MIS-C. Also, lung mechanics variables were associated with mortality, being  $DP \ge 15$  cmH<sub>2</sub>O the best discriminator.

Pediatric ARDS phenotypes in critical COVID-19: implications for therapies and outcomes.

**BACKGROUND** 

Respiratory failure has been the leading cause of hospital admission and death during the COVID-19 pandemic.

Severe hypoxemia due to pneumonia and acute respiratory distress syndrome (ARDS) is a frequent cause of

admission to intensive care for advanced respiratory support<sup>1</sup>. Since the first cohorts' description in China and

Europe, many authors reported discrepancies between the severity of the oxygenation and the relatively spared

pulmonary mechanics in a subgroup of patients<sup>2,3</sup>

In addition, atypical lung imaging in chest computed tomography and histopathology with lung microvascular

involvement raises questions about whether the underlying pathophysiology in COVID-19 is like that of ARDS

in other etiologies<sup>2,4,5,6</sup>. Thus, a new entity called C-ARDS (COVID-19 associated ARDS) is proposed by some

researchers<sup>7-9</sup>.

Pediatric COVID-19 critical illness is heterogeneous and infrequent 10-12. The most common causes of admission

to the pediatric intensive care unit (PICU) are respiratory failure and multisystem inflammatory syndrome in

children (MIS-C), 10-15. Nonetheless, cases of non-cardiopulmonary involvement are frequent 14-16. While the low

morbidity and mortality in the general pediatric population is reassuring, there is a significant gap in knowledge

in identifying high-risk subgroups, such as those who develop pediatric ARDS (PARDS) or multiorgan

failure. 11,12,16

4

Invasive mechanical ventilation (MV) for pediatric COVID-19 at PICU has been reported between 30 to 70% in

different cohorts<sup>11,13,15,17-19</sup>. Surprisingly, specific information on PARDS related to COVID-19 is scarce. The

heterogeneous nature of lung involvement was initially described as distinctive phenotypes in adult C-ARDS

based on pulmonary mechanics, type L and type H<sup>2</sup>. Although still controversial, different phenotypes might

have implications for therapy and outcomes<sup>20,21</sup>. This principle also applies to respiratory failure and PARDS in

the general PICU population. A better description of PARDS characteristics is urgently needed to improve

guidelines and recommendations and ultimately improve outcomes for critically ill children.

We hypothesize that two different phenotypes can be observed in critically ill children with PARDS associated

with COVID-19: 1) PARDS in patients diagnosed with MIS-C (MIS-PARDS), with almost normal compliance,

low driving pressure, and extrapulmonary organ failure; 2) PARDS with severe COVID-19 pneumonia (C-

PARDS), with low compliance, profound hypoxemia, and less frequent multiorgan failure.

This study aimed to describe lung mechanics in critically ill children with PARDS due to COVID-19, analyzing

sub-groups of MIS-C and C-PARDS and outcomes.

PATIENTS AND METHODS

A concurrent observational study was conducted in four PICU's of pediatric referral hospitals in Perú: Hospital

Nacional Hipolito Unanue, Hospital de Emergencias de Villa El Salvador, Hospital Regional del Cusco,

Hospital Edgardo Rebagliati Martins. Institutional review boards' approval for data collection was obtained at

each site, waiving informed consent

The study included patients between 1 month and 17 years of age from the PICU Registry cohort of COVID-19

admitted between April 1 and August 31, 2021. Briefly, this observational registry records the treatment and the

management of critical COVID-19 patients admitted to participating centers. Deidentified data were gathered

from administrative and clinical databases for benchmarking, including demographics, clinical and

physiological parameters, therapeutic interventions, and outcomes. Critical COVID-19 definition included

patients with SARS-CoV-2 rt-PCR in respiratory airways or antibody profile compatible with acute COVID-19

infection (IgG (+)) and CT scan with characteristics of acute COVID-19 infection. In addition, patients who met

the case definition for MIS-C were also included, even lacking a confirmed microbiological diagnosis of SARS-

CoV-2 infection, to include all the causes of pediatric critical COVID-19, requiring PICU admission, as

previously defined. 11,12,22,23

Patients with a clinical and microbiological profile of SARS-CoV-2 infection at PICU admission, receiving

invasive MV, and meeting PALICC criteria for PARDS<sup>24</sup>, were included in the analysis. Pneumonia severity

was based on PAHO definitions<sup>25</sup>. Patients were excluded if they had uncorrected congenital heart, pre-existing

lung or airway disease, chronic respiratory failure requiring long-term MV and tracheostomy, severe left

ventricular dysfunction failure with ejection fraction less than 30%<sup>26</sup> and COVID-19 with primary neurological

involvement. In addition, patients with spontaneous breathing effort and endotracheal tube air leak were

excluded due to possible interference with data acquisition and unreliable quasi-static lung mechanics

measurements and calculations.

During the first 72 hrs after initiation of MV, all patients were screened at 8 AM and 8 PM. PARDS severity

was determined following PALICC criteria, according to the oxygenation index, classified as mild (4 to <8),

moderate (8 to <16), and severe ( $\geq$  16).<sup>24</sup> When hypoxemia was the lowest, all the parameters were recorded.

Organ dysfunction was assessed by the treating physician based on definitions by the international pediatric

sepsis consensus conference<sup>27</sup>, and multiorgan dysfunction was defined as  $\geq 3$  organ dysfunctions. Vasoactive

support was quantified through Vasoactive-Inotropic Score (VIS)<sup>28</sup>. Cardiac function was evaluated in all

patients with transthoracic echocardiography performed by an experienced clinician, defining cardiac

5

dysfunction as any alteration in systolic and diastolic function, and severe dysfunction was defined as ejection

fraction less than 40% <sup>26, 29</sup>. In assessing organ dysfunction, we consider the worst value in the first 72 h after

admission. Analyzed outcomes were duration of MV, Ventilator-free days at day 30 (VFD), Length of PICU

stay, length of hospital stay, and PICU mortality.

Patients were classified into the MIS-C (MIS-PARDS) and COVID-19 pneumonia (C-PARDS) phenotypes. All

patients fulfilling MIS-C diagnostic criteria (World Health Organization (WHO), Royal College of Paediatrics

and Child Health, or Centers for Disease Control and Prevention) were classified as MIS-PARDS<sup>30-32</sup>. C-

PARDS group consisted of PARDS patients fulfilling COVID-19 pneumonia according to the modified case

definitions of the World Health Organization (WHO).<sup>33</sup> Supplementary table 1 shows detailed patient

classifications according to diagnostic tests.

Lung mechanics were measured in a volume control mode as previously described. 34,35 Ventilator parameters

[peak inspiratory pressure (PIP), plateau pressure (Pplat), PEEP, expiratory VT (VTE), and inspiratory time

(IT), and arterial blood gases were registered, and PaO<sub>2</sub>/FiO<sub>2</sub> ratio and Oxygenation Index (OI) were calculated.

The components of working pressure, resistive (PIP – Pplat) and elastic (driving pressure,  $\Delta P = Pplat-PEEP$ ),

were calculated for each subject. Respiratory system compliance (C<sub>RS</sub>, mL·cmH2O<sup>-1</sup>·kg<sup>-1</sup>) was calculated

according to the standard equation.

Statistical analysis

The data obtained were entered in a database on Microsoft® Excel (version for Windows 2016), reviewed,

cleaned, and analyzed in STATA v.16 (StataCorp LP, Texas, USA). Frequencies and percentages were used to

describe the categorical variables, while median and interquartile range (IQR) were used for quantitative data

since the assumption of normality was not met. In addition, a bivariate analysis was performed between MIS-

PARDS and C-PARDS and for survivors and non-survivors, using Fisher's exact test for categorical variables

and the Mann-Whitney U test for quantitative variables. A p-value less than 0.05 was considered statistically

significant. Finally, receiver operator characteristic (ROC) curves were built for DP, C<sub>RS</sub>, and Pplat, to evaluate

their accuracy as discriminators for mortality as an outcome.

**RESULTS** 

6

During the study period, 123 critically ill COVID-19 children were admitted to the participating units, 30 with

PARDS diagnosis, and all of them met the selection criteria for the analysis (Figure 1). The median age was 7.5

years (4-11), 63% were intubated before PICU admission, 50% of the patients suffered moderate PARDS, 30%

severe, and 30% developed multiorgan failure. PICU median length of stay was seven days (5-9), and mortality was 23% (Table 1). The primary cause of death was refractory shock and multiorgan failure.

The most frequent clinical signs and symptoms were dyspnea (77%), fever (67%), and abdominal pain (43%). Regarding the COVID-19 diagnosis, RT-PCR was positive in 38% of PARDS patients, and serology tests showed that 12/26 patients were IgM/IgG positive and 12/26 were IgM negative/IgG positive. Only one case was positive for IgG and RT-PCR. Viral co-infection and bacterial superinfection were ruled out with PCR for viral respiratory pathogens and blood and tracheal secretion cultures.

In 5 cases, left ventricular dysfunction was observed in echocardiograms, but none were severe (Supplementary Table 2). Coronary aneurysms were reported in two patients. The most frequent vasopressors were epinephrine (67%) and norepinephrine (57%), and VIS was 22 (12 to 50) (Table 2).

Fourteen patients (47%) were classified in MIS-PARDS phenotype and 16 (53%) children in C-PARDS phenotype. MIS-PARDS had more frequent abdominal pain and rash, while the C-PARDS group had more respiratory symptoms, like cough and lower oxygen saturation (Table 1). All patients with MIS-PARDS phenotype had a negative RT-PCR, and it was positive in 62.5% of the C-PARDS subgroup (p < 0.001). On the contrary, IgM(-)/IgG(+) profile was observed in 64.3% of MIS-PARDS and only in 16.7% of C-PARDS (p=0.02). (Table 1)

MIS-PARDS patients had significantly more cardiac dysfunction than the C-PARDS group (71 vs. 25%, p=0.03), and no other differences were found in organ failures and vasoactive support (Table 2). Mild left ventricular dysfunction was observed in 42% of MIS-PARDS and 6% of C-PARDS (supplementary table 2), but no severe dysfunction was found. C-PARDS group had more profound hypoxemia, higher Pplat and DP, and lower  $C_{RS}$ , all p<0.05, while MIS-PARDS had a higher PIP-Pplat gradient (p=0.04) (Table 3 and Figure 2). There was a trend toward higher mortality in the C-PARDS group compared to MIS-PARDS (38 vs. 7%, p=0.09). MV free days were significantly lower in C-PARDS than MIS-PARDS (p=0.02), without differences in other outcomes.

When comparing survivors and non-survivors, there were no significant differences in demographics, organ dysfunctions, vasoactive support, and gas exchange. In addition, there were no significant differences in  $V_T$  and PEEP between both groups, but  $C_{RS}$  was significantly lower in non-survivors; thus, PIP, Pplat, and DP were higher (all p< 0.05).

ROC of DP and mortality showed an AUC of 0.91 (95% CI 0.81-1.00), and the best cut point was 15 cm $H_2O$  (100% sensitivity and 87% specificity). AUC for Elastance (1/CRS) was 0.89 (95% CI 0.77-1.00), with a best

7

cut point of 2.7 (C<sub>RS</sub> 0.37) (85.7% sensibility and 91.3% specificity). AUC for Pplat was 0.89 (95% CI 0.76-

1.00), with a best-cut point of 28 (C<sub>RS</sub> 0.37) (100% sensibility and specificity 87%). (Supplementary figure)

DISCUSSION

8

The main result of this multicentric study of PARDS associated with pediatric critical COVID-19 was the

description of two different phenotypes, C-PARDS and MIS-PARDS. C-PARDS is similar to other severe viral

pneumonia, and we observed more frequent respiratory symptoms, hypoxia, and a positive COVID-19 rt-PCR

in upper respiratory airways. On the other hand, MIS-PARDS had abdominal pain, mucocutaneous signs, and

the characteristic MIS-C profile of IgG (+), IgM (-), and negative SARS-CoV-2 RT-PCR. In agreement with

these observations, the lung mechanics parameters were different between subgroups: C-PARDS had higher

Pplat and DP and lower C<sub>RS</sub> and PIP-Pplat than MIS-PARDS. Regarding mortality, similar differences were

observed between survivors and non-survivors. DP, Elastance (1/C<sub>RS</sub>), and Pplat were good discriminators for

mortality, but DP had the best performance.

Remarkably, the C<sub>RS</sub> of C-PARDS was close to the C<sub>RS</sub> reported in other pediatric cohorts of viral PARDS<sup>31</sup> and

other restrictive lung diseases<sup>38</sup>. Regarding outcomes, mortality was not statistically different between C-

PARDS and MIS-PARDS. VFD were significantly lower in this group, probably due to the primary pulmonary

dysfunction observed in C-PARDS. Only one patient out of 14 died in the MIS-PARDS group, in accordance

with the usual overall good prognosis of MIS-C. 11,12,15

The mortality of our cohort may seem high, but when analyzing survival, many studies report between 10 and

70% of mortality in PARDS.<sup>37</sup> Also, there are reports regarding differences in mortality between high and low-

middle-income countries. 39,40 It is very interesting that in the current study, previous known variables associated

with mortality in PARDS and in pediatric critical COVID-19, like organ failures and hypoxemia severity, were

not different between survivors and non-survivors. 37,38, 41-45

A surprising result was the difference in the respiratory mechanics between the clinical phenotypes. The cohort

fulfilled PARDS and critical COVID-19 criteria but with different characteristics. C-PARDS group's features

were like a classic moderate to severe primary ARDS. 46 On the contrary, the main characteristic of the MIS-

PARDS group was an uncoupling between the respiratory mechanics and gas exchange. An attractive

hypothesis is that the underlying pathophysiology leading to PARDS might be different in both phenotypes. In

C-PARDS, airway epithelium and pneumocytes injury might be the initial alteration resulting in alveolar

collapse with inflammatory exudate, neutrophils, and macrophages. On the other hand, in the context of

systemic dysregulated inflammation, MIS-PARDS, the initial injury might depend on capillary endothelium, leading to interstitial edema and then flooding of alveolar space. It is important to recall severe left ventricular dysfunction was not observed in the cohort, but mild dysfunction was frequently reported, a common finding in critically ill children<sup>26,47-49</sup>. In addition, no signs of cardiogenic acute pulmonary edema were present.

A possible explanation for the trend toward higher mortality is the low  $C_{RS}$  of the C-PARDS group, resulting in higher DP, a previous parameter associated with mortality in ARDS patients. In an exploratory analysis, we found that DP was close to the ideal clinical discriminator for mortality. Interestingly, the best cut-off was 15 cm $H_2O$ . In 2 retrospective studies of children under MV due to acute hypoxemic respiratory failure, high DP ( $\geq$  15 cm $H_2O$ ) was associated with less VFD but not mortality. This threshold also was described in adults. In a meta-analysis that included nine prospective trials and more than 3,500 patients, Amato et al. showed that DP was the best variable correlated with survival, even in patients within the usual thresholds of a lung-protective MV strategy<sup>50</sup>. Even more, interventions that resulted in a decrease in DP were associated with a greater survival rate. Other authors have confirmed the association between DP and ARDS outcomes, and a threshold of 15 cm $H_2O$  has been incorporated into most lung-protective protocols.<sup>51,52</sup>

Our study has some limitations. We report respiratory mechanics in quasi-static conditions in VCV mode; thus, they cannot be extrapolated to other modes of MV with a deaccelerating flow, frequently used in pediatrics<sup>44</sup>. Presented data is the worst during the first 72h of admission, so time-dependent variables are not analyzed<sup>43</sup>. We did not investigate other parameters associated with PARDS severity or outcomes, i.e., dead space or mechanical power, because it was not part of our objective<sup>53-55</sup>. As in many multicenter studies, there might be differences in ventilatory strategy between sites, and comparisons were not possible given the heterogeneity of cases per center. The lack of consistency, especially PEEP titration, might influence some calculations of pulmonary mechanics. The small number of patients in each group might lead to type II statistical errors in some analyzed variables. There is also a risk of type I statistical errors, given the absence of statistical correction for multiple comparisons. Finally, the small number of cases probably influenced the lack of a statistical difference in mortality between C-PARDS and MIS-PARDS groups, although the difference was clinically relevant (38 vs. 7%). Nonetheless, we consider our results important to define high-risk groups of children with critical COVID-19 and as hypothesis-generating data for PARDS in the general PICU population.

# CONCLUSIONS

Our data show two different clinical phenotypes of pediatric critical COVID-19 PARDS with distinctive pulmonary mechanics features. C-PARDS group characteristics were like a classic moderate to severe primary

ARDS. A decoupling between compliance and hypoxemia was more frequent in MIS-PARDS. Regarding

outcomes, C-PARDS had less VFD and a trend toward higher mortality than MIS-PARDS. Data from the quasi-

static calculations were associated with mortality; specifically, a DP  $\geq$  15 cmH2O was the best discriminator.

Standardized pulmonary mechanics measurements in PARDS might reveal essential information to tailor the

ventilatory strategy. Future studies may include these data for subgroup classifications and outcomes and

ultimately improve the care of critically ill children.

Acknowledgments

None

**Authors' contributions** 

Conceptualization and design: JDR, CMM, NAA. Data collection: JDR, YLD, PCV, CMR, MQC, MCA, GQF,

MTP. Data curation: JDR, PVH, FD. Formal analysis and investigation: JDR, FD, PVH. Draft preparation: JDR,

PVH, FD; Manuscript review and editing: JDR, PVH, FD, PC. JDR supervised the study at all stages. All

authors read and approved the final version of the manuscript.

**Funding** 

No funding was involved in this research

Availability of supporting data

The data supporting this study's findings are available from the corresponding author, FD, upon reasonable

request.

Compliance with ethical standards.

Conflicts of interests.

The authors declare no conflicts of interest.

Ethical approval

10

Local IRB of each participating center approved the study (Approval letters 088-2021-CIEI-HNHU, 011-2021-CIEI-HEVES, 001-2021-COVID-HR, 42-IETSI-ESSALUD-2020).

#### **Informed consent**

Informed consent was waived due to gathering anonymized data previously collected for administrative and benchmarking purposes.

## **REFERENCES**

 Chen N, Zhou M, Dong X, et al (2020) Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 395:507-13.

DOI: 10.1016/S0140-6736(20)30211-7

 Luciano Gattinoni, Davide Chiumello, Pietro Caironi (2020) COVID-19 pneumonia: different respiratory treatments for different phenotypes? Intensive Care Med 46(6):1099-1102

DOI: 10.1007/s00134-020-06033-2

3. Tsolaki V, Zakynthinos GE, Makris D (2020) The ARDSnet protocol may be detrimental in COVID-19. Crit Care 24:351.

DOI: 10.1186/s13054-020-03081-4

 Hendrickson KW, Peltan ID, Brown SM (2021) The Epidemiology of Acute Respiratory Distress Syndrome Before and After Coronavirus Disease 2019. Crit Care Clin 37:703–716.

DOI: 10.1016/j.ccc.2021.05.001

Ackermann M, Verleden SE, Kuehnel M, et al (2020) Pulmonary Vascular Endothelialitis,
 Thrombosis, and Angiogenesis in Covid-19. New Engl J Med 383:120–128.

DOI: 10.1056/NEJMoa2015432

- Haberecker M, Schwarz EI, Steiger P, et al (2021) Autopsy-Based Pulmonary and Vascular Pathology: Pulmonary Endotheliitis and Multi-Organ Involvement in COVID-19 Associated Deaths. Respiration 1–11. DOI: 10.1159/000518914
- Marini JJ, Gattinoni L (2020) Management of COVID-19 Respiratory Distress. JAMA 323:2329–2330.
  DOI: 10.1001/jama.2020.6825

8. Pfortmueller CA, Spinetti T, Urman RD, et al (2021) COVID-19-associated acute respiratory distress

syndrome (CARDS): Current knowledge on pathophysiology and ICU treatment - A narrative review.

Best Pract Res Clin Anaesthesiol 35:351–368.

DOI: 10.1016/j.bpa.2020.12.011

9. Acosta MAT, Singer BD (2020) Pathogenesis of COVID-19-induced ARDS: implications for an

ageing population. Eur Respir J 56:2002049.

DOI: 10.1183/13993003.02049-2020

10. Parcha V, Booker KS, Kalra R, et al (2021) A retrospective cohort study of 12,306 pediatric COVID-

19 patients in the United States. Sci Rep-uk 11:10231.

DOI: 10.1038/s41598-021-89553-1

11. Gonzalez-Dambrauskas S, Vasquez-Hoyos P, Camporesi A, Cantillano EM, Dallefeld S, Dominguez-

Rojas J, et al. Pediatric critical COVID-19 and mortality in a multinational cohort. Medrxiv.

2021;2021.08.20.21262122.

DOI: 10.1101/2021.08.20.21262122

12. Feldstein LR, Tenforde MW, Friedman KG, Newhams M, Rose EB, Dapul H, et al. Characteristics and

Outcomes of US Children and Adolescents With Multisystem Inflammatory Syndrome in Children

(MIS-C) Compared With Severe Acute COVID-19. JAMA. 2021;325:1074–87.

DOI: 10.1001/jama.2021.2091

13. Fisler G, Izard SM, Shah S, et al (2020) Characteristics and risk factors associated with critical illness

in pediatric COVID-19. Ann Intensive Care 10:171.

DOI: 10.1186/s13613-020-00790-5

14. González-Dambrauskas S, Vásquez-Hoyos P, Camporesi A, et al (2020) Pediatric Critical Care and

COVID19. Pediatrics 146:e20201766.

DOI: 10.1542/peds.2020-1766

15. Bustos B R, Jaramillo-Bustamante JC, Vasquez-Hoyos P, et al.: Pediatric Inflammatory Multisystem

Syndrome Associated With SARS-CoV-2: A Case Series Quantitative Systematic Review. Pediatr

Emerg Care 2020; 37:44-47

12

DOI: 10.1097/PEC.0000000000002306

16. Bourgeois FT, Gutiérrez-Sacristán A, Keller MS, et al (2021) International Analysis of Electronic Health Records of Children and Youth Hospitalized With COVID-19 Infection in 6 Countries. Jama Netw Open 4:e2112596.

DOI: 10.1001/jamanetworkopen.2021.12596

17. Kanthimathinathan HK, Buckley H, Lamming C, et al (2021) Characteristics of Severe Acute Respiratory Syndrome Coronavirus-2 Infection and Comparison With Influenza in Children Admitted to U.K. PICUs. Critical Care Explor 3:e0362.

DOI: 10.1097/cce.0000000000000362

18. Chao JY, Derespina KR, Herold BC, et al (2020) Clinical Characteristics and Outcomes of Hospitalized and Critically Ill Children and Adolescents with Coronavirus Disease 2019 (COVID-19) at a Tertiary Care Medical Center in New York City. J Pediatrics 223:14-19.e2

DOI: 10.1016/j.jpeds.2020.05.006

 Lorenzo VB, Nascimento-Carvalho CM (2021) Differences between children with severe acute lower respiratory infection with or without SARS-Cov-2 infection. J Infection 83:e1–e3.

DOI: 10.1016/j.jinf.2021.05.038

Gattinoni L, Marini JJ (2021) Isn't it time to abandon ARDS? The COVID-19 lesson. Crit Care
 25:326. DOI: 10.1186/s13054-021-03748-6

21. Attaway AH, Scheraga RG, Bhimraj A, et al (2021) Severe covid-19 pneumonia: pathogenesis and clinical management. BMJ 372:n436.

DOI: 10.1136/bmj.n436

 Reiff DD, Mannion ML, Samuy N, Scalici P, Cron RQ. Distinguishing active pediatric COVID-19 pneumonia from MIS-C. Pediatr Rheumatol (2021) 19:21.

DOI: 10.1186/s12969-021-00508-2.

23. Rimensberger PC, Kneyber MCJ, Deep A, Bansal M, Hoskote A, Javouhey E, Jourdain G, Latten L, MacLaren G, Morin L, et al. Caring for Critically Ill Children With Suspected or Proven Coronavirus Disease 2019 Infection: Recommendations by the Scientific Sections' Collaborative of the European Society of Pediatric and Neonatal Intensive Care. Pediatr Crit Care Me (2020) 22:56–67.

DOI: 10.1097/pcc.0000000000002599

24. Pediatric Acute Lung Injury Consensus Conference Group (2015) Pediatric acute respiratory distress syndrome: consensus recommendations from the Pediatric Acute Lung Injury Consensus Conference. Pediatr Crit Care Med; 16(5):428-39.

DOI: 10.1097/PCC.0000000000000350

DOI:10.1542/peds.2021-052888f

- 25. https://www.paho.org/en/case-definitions-covid-19-surveillance-16-december-2020
- 26. Alexander PMA, Checchia PA, Ryerson LM, Bohn D, Eckerle M, Gaies M, Laussen P, Jeffries H, Thiagarajan RR, Shekerdemian L, et al. Cardiovascular Dysfunction Criteria in Critically Ill Children: The PODIUM Consensus Conference. Pediatrics (2022) 149:S39–S47.
- 27. Goldstein B, Giroir B, Randolph A (2005) International pediatric sepsis consensus conference: definitions for sepsis and organ dysfunction in pediatrics. Pediatr Crit Care Med 6(1):2-8. DOI: 10.1097/01.PCC.0000149131.72248.E6.
- McIntosh AM, Tong S, Deakyne SJ, Davidson JA, Scott HF (2017) Validation of the Vasoactive-Inotropic Score in Pediatric Sepsis. Pediatr Crit Care Med. 18(8):750-757.
   DOI: 10.1097/PCC.0000000000001191.
- 29. Nagueh SF, Smiseth OA, Appleton CP (2016) Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 29(4):277-314. DOI: doi: 10.1016/j.echo.2016.01.011.
- WHO. Multisystem inflammatory syndrome in children and adolescents with COVID-19. May 15, 2020.
  - https://www.who.int/news-room/commentaries/detail/multisystem-inflammatory-syndrome-in-children-and-adolescents-with-covid-19 . Accessed December, 15<sup>th</sup> , 2021.
- 31. Centers for Disease Control and Prevention. Multisystem Inflammatory Syndrome in Children (MIS-C) Associated with Coronavirus Disease 2019 (COVID-19). Distributed via the CDC Health Alert Network. May 14, 2020
- 32. Royal College of Paediatrics and Child Health. Guidance: Paediatric multisystem inflammatory syndrome temporally associated with COVID-19. May 1, 2020.

33. World Health Organization (2020). Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected: interim guidance, 13 March 2020. World Health Organization. https://apps.who.int/iris/handle/10665/331446

34. Cruces P, González-Dambrauskas S, Quilodrán J, et al (2017) Respiratory mechanics in infants with severe bronchiolitis on controlled mechanical ventilation. BMC Pulm Med 17:129

DOI: 10.1186/s12890-017-0475-6

Khemani RG, Bart RD, Newth CJL (2007) Respiratory monitoring during mechanical ventilation.
 Paediatrics and Child Health 5(17):193-201

DOI:10.1016/j.paed.2007.02.006

36. van Schelven P, Koopman AA, Burgerhof J, Markhorst DG, Blokpoel R, Kneyber M (2021) Driving Pressure Is Associated with Outcome in Pediatric Acute Respiratory Failure. Pediatr Crit Care Med Publish Ahead of Print

DOI: 10.1097/PCC.0000000000002848

37. Schouten LR, Veltkamp F, Bos AP, van Woensel JB, Serpa Neto A, Schultz MJ, et al. (2016) Incidence and mortality of acute respiratory distress syndrome in children: a systematic review and meta-analysis. Crit Care Med 44(4):819–29.

DOI: 10.1097/CCM.0000000000001388

38. Kim SY, Kim B, Choi SH, Kim JD, Sol IS, Kim MJ et al (2018) Oxygenation Index in the First 24 Hours after the Diagnosis of Acute Respiratory Distress Syndrome as a Surrogate Metric for Risk Stratification in Children. Acute Critical Care 33:222–229.

DOI: 10.4266/acc.2018.00136

39. Munoz AC, Tasayco J, Morales W, Moreno L, Zorrilla D, Stapleton A, Pajuelo P, Reyes G, Estupiñan M, Seminario R, et al. (2021) High incidence of stroke and mortality in pediatric critical care patients with COVID-19 in Peru. Pediatr Res 1–5.

doi: 10.1038/s41390-021-01547-x

40. Kitano T, Kitano M, Krueger C, Jamal H, Rawahi HA, Lee-Krueger R, Sun RD, Isabel S, García-Ascaso MT, Hibino H, et al. (2021) The differential impact of pediatric COVID-19 between high-income countries and low- and middle-income countries: A systematic review of fatality and ICU admission in children worldwide. Plos One 16:e0246326.

doi: 10.1371/journal.pone.0246326

41. Panico FF, Troster EJ, Oliveira CS, et al (2015) Risk Factors for Mortality and Outcomes in Pediatric Acute Lung Injury/Acute Respiratory Distress Syndrome. Pediatr Crit Care Me 16:e194–e200.

DOI: 10.1097/PCC.00000000000000490

42. Wong JJM, Lee SW, Tan HL, et al (2020) Lung-Protective Mechanical Ventilation Strategies in Pediatric Acute Respiratory Distress Syndrome. Pediatr Crit Care Med 16(7):e194-200.

DOI: doi: 10.1097/PCC.0000000000000490

43. López-Fernández Y, Azagra AM, Oliva P de la, et al (2012) Pediatric Acute Lung Injury Epidemiology and Natural History Study. Crit Care Med 40:3238–3245.

DOI: 10.1097/CCM.0b013e318260caa3

44. Khemani RG, Smith L, Lopez-Fernandez YM, Kwok J, Morzov R, Klein MJ, et al (2019) Paediatric acute respiratory distress syndrome incidence and epidemiology (PARDIE): an international, observational study. Lancet Respir Med 7(2):115–28.

DOI: 10.1016/S2213-2600(18)30344-8

45. Weiss SL, Asaro LA, Flori HR, Allen GL, Wypij D, Curley MAQ, et al (2017) Multiple Organ Dysfunction in Children Mechanically Ventilated for Acute Respiratory Failure Pediatr Crit Care Med 18:319–29.

DOI: 10.1097/PCC.0000000000001091

 Pelosi P, D'Onofrio D, Chiumello D, Paolo S, Chiara G, Capelozzi VI, et al. (2003). European Respiratory Journal 22:48s-56.

DOI: 10.1183/09031936.03.00420803

 Ginsburg S, Conlon T, Himebauch A, Glau C, Weiss S, Weber MD, O'Connor MJ, Nishisaki A.
 (2021) Left Ventricular Diastolic Dysfunction in Pediatric Sepsis: Outcomes in a Single-Center Retrospective Cohort Study. Pediatr Crit Care Med 22:275–285.

doi:10.1097/pcc.0000000000002668

48. Williams FZ, Sachdeva R, Travers CD, Walson KH, Hebbar KB. (2016) Characterization of Myocardial Dysfunction in Fluid- and Catecholamine-Refractory Pediatric Septic Shock and Its Clinical Significance. J Intensive Care Med 34:17–25.

doi:10.1177/0885066616685247

49. Ranjit S, Aram G, Kissoon N, Ali MK, Natraj R, Shresti S, Jayakumar I, Gandhi D. (2014) Multimodal Monitoring for Hemodynamic Categorization and Management of Pediatric Septic Shock. Pediatr Crit Care Me 15:e17–e26.

doi: 10.1097/pcc.0b013e3182a5589c

 Amato MB, Meade MO, Slutsky AS, Brochard L, Costa EL, Schoe- nfeld DA, et al (2015) Driving pressure and survival in the acute respiratory distress syndrome. N Engl J Med 372(8):747-755.

DOI: 10.1056/NEJMsa1410639.

51. Griffiths MJD, McAuley DF, Perkins GD, et al (2019) Guidelines on the management of acute respiratory distress syndromeBMJ Open Respiratory Research 6:e000420.

DOI: 10.1136/bmjresp-2019-000420

52. Romano MLP, Maia IS, Laranjeira LN, et al (2020) Driving Pressure–limited Strategy for Patients with Acute Respiratory Distress Syndrome. A Pilot Randomized Clinical Trial. Ann Am Thorac Soc 17:596–604.

DOI: 10.1513/annalsats.201907-506oc

53. Díaz F, González-Dambrauskas S, Cristiani F, et al (2021) Driving Pressure and Normalized Energy Transmission Calculations in Mechanically Ventilated Children Without Lung Disease and Pediatric Acute Respiratory Distress Syndrome. Pediatr Crit Care Med Publish Ahead of Print.

DOI: 10.1097/pcc.0000000000002780

54. Bhalla AK, Belani S, Leung D, Newth CJL, Khemani RG (2015) Higher Dead Space Is Associated with Increased Mortality in Critically Ill Children. Crit Care Med 43:2439–45.

DOI: 10.1097/CCM.0000000000001199

55. Yehya N, Bhalla AK, Thomas NJ, Khemani RG (2016) Alveolar Dead Space Fraction Discriminates Mortality in Pediatric Acute Respiratory Distress Syndrome. Pediatr Crit Care Med 17:101–9.

DOI: 10.1097/PCC.00000000000000613

Table 1. Demographic and clinical characteristics of pediatric respiratory distress syndrome associated with COVID-19 according to the clinical phenotypes and outcome.

	All	MIS-PARDS	C-PARDS	Survivors	Non-survivors
	n. 30	n. 14	n. 16	n. 23	n. 7
Age, years	7.5 (4-11)	7 (6-9)	10 (2-13)	8 (5-12)	7 (3-11)
Male sex	18 (60)	12 (67)*	6 (33)	15 (65)	3 (43)
Weight, kg	30 (21-45)	32 (21-45)	28 (13-57)	30 (21-54)	25 (15-34)
SpO2, %	87 (82-90)	89 (86-95)*	85 (78-88)	88 (82-94)	85 (79-88)
Intubation prior to PICU	19 (63)	9 (64)	10 (63)	14 (61)	5 (71)
Signs and Symptoms					
Fever	20 (67)	12 (86)	8 (50)	14 (61)	6 (86)
Respiratory					
Respiratory distress	24 (80)	12 (86)	12 (75)	19 (83)	5 (71)
Chest Retractions	7 (23)	4 (29)	3 (19)	7 (30)	0 (0)
Oxygen desaturation	21 (70)	7 (50)*	14 (88)	15 (65)	6 (86)
Rhinorrhea	3 (10)	0 (0)	3 (19)	1 (4)	2 (29)
Cough	7 (23)	0 (0)*	7 (44)	5 (22)	2 (29)
Mucocutaneous					
Rash	5 (17)	5 (36)*	0 (0)	5 (22)	0 (0)
Red eye	3 (10)	3 (21)	0 (0)	2 (9)	1 (14)
Abdominal pain	13 (43)	12 (86)*	1 (6)	12 (52)	1 (14)
Diarrhea/vomiting	4 (13)	2 (14)	2 (13)	4 (17)	0 (0)
SARS-CoV-2 testing					
Viral test, positive	10/26	0/14*	10/16	6/20	4/6
(Not tested)	4 (13)	3 (21)	1 (6)	3 (13)	1 (14)
Antibody test					
IgM [+]/IgG [+]	12/26	4/14	8/12	9/21	3/5
IgM [-]/IgG [+]	12/26	10/14*	2/12	12/21*	0/5
(Not tested)	4 (13)	0 (0)	4 (25)	2 (9)	2 (29)
Outcomes					
MV duration, hours	120 (72-168)	108 (72-144)	120 (84-216)	120 (72-232)	120 (72-168)
MV free days	22 (7-24)	23 (21-25)*	12 (0-23)	-	-
PICU length of stay, days	7 (5-9)	6 (5-9)	7 (5-10)	7 (6-15)*	5 (3-7)
Hospital length of stay, days	11 (7-16)	13 (8-14)	9 (7-18)	13 (8-18)*	6 (4-7)

ICU death	7 (23)	1 (7)	6 (38)	-	-
-----------	--------	-------	--------	---	---

Data are n (%) or median (IQR).

Abbreviations: SpO2, pulse oximetry saturation; MV, mechanical ventilation; PARDS, Pediatric Acute Respiratory Distress Syndrome; C-PARDS, PARDS associated with COVID-19 pneumonia; MIS-PARDS, PARDS associated with multisystem inflammatory syndrome in children

Table 2. Organ failure and vasoactive support in pediatric respiratory distress syndrome associated with COVID-19 according to the clinical phenotypes and outcomes.

	All	MISC-PARDS	C-PARDS	Survivors	Non-survivors
	n. 30	n. 14	n. 16	n. 23	n. 7
Organ dysfunction					
Pulmonary	30 (100)	14 (100)	16 (100)	23 (100)	7 (100)
Hemodynamic	29 (96)	14 (100)	15 (94)	22 (96)	7 (100)
Another organ (any)	17 (57)	6 (43)	11 (69)	12 (52)	5(71)
Hematological	10 (33)	3 (21)	7 (44)	8 (35)	2 (29)
Renal	3 (10)	1 (7)	2 (13)	2 (9)	1 (14)
Neurological	6 (20)	3 (21)	3 (19)	4 (17)	2 (29)
GI/Hepatic	3 (10)	2 (14)	1 (6)	3 (13)	0 (0)
Number of					
organ dysfunctions					
1	5 (17)	2 (14)	3 (19)	5 (22)	0 (0)
2	16 (53)	7 (50)	9 (56)	12 (52)	4 (57)
≥ 3	9 (30)	5 (36)	4 (25)	6 (26)	3 (43)
Vasoactive support					
Any vasoactive	29	14 (100)	15 (94)	22 (97)	7 (100)
Vasopressors	19 (63)	10 (71)	9 (56)	13 (57)	6 (86)
Inotropes	24 (80)	13 (93)	11 (69)	18 (78)	6 (86)
Median VIS	22 (12-50)	31 (19-50)	18 (10-45)	20 (12-50)	30 (10-60)

Data are n (%) or median (IQR).

<sup>\*</sup>p<0.05 using Fisher's exact test or Mann-Whitney U test.

Abbreviations: GI, gastrointestinal; VIS, vasoactive inotropic scale; PARDS: Pediatric Acute Respiratory Distress Syndrome; C-PARDS, PARDS associated with COVID-19 pneumonia; MIS-PARDS, PARDS associated with multisystem inflammatory syndrome in children.


Table 3. Gas exchange, mechanical ventilation settings, and lung mechanics in pediatric respiratory distress syndrome associated with COVID-19 according to the clinical phenotypes and outcome.

	All	MISC-PARDS	C-PARDS	Survivors	Non-survivors
	n. 30	n. 14	n. 16	n. 23	n. 7
Oxygenation					
$FiO_2$	60 (45-100)	53 (40-60)	60 (48-100)	55 (45-60)	100 (45-100)
PaO <sub>2</sub> , mmHg	80 (60-100)	92 (70-129)	77 (55-83)	85 (60-100)	77 (56-80)
PaO <sub>2</sub> /FIO <sub>2</sub>	130 (85-228)	163 (129-252)*	96 (74-150)	130 (98-230)	80 (70-171)
$PaO_2/FIO_2 < 100$	12 (40)	6 (38)*	12 (86)	15 (65)	3 (43)
P(A-a) O <sub>2</sub> , mmHg	246 (165-399)	235 (141-305)	336 (175-564)	240 (141-330)	547 (182-580)
Oxygenation index	9.7 (6.1-19.9)	7.5 (4.2-13.6)*	11.9 (7.8-23.0)	8.4 (4.3-15)	22.5 (8.6-24)
PARDS severity					
Mild (4 to <8)	6 (20)	4 (29)	2 (13)	6 (26)	0 (0)
Moderate (8 to <16)	15 (50)	7 (50)	8 (50)	12 (52)	3 (43)
Severe (≥ 16)	9 (30)	3 (21)	6 (37)	5 (22)	4 (57)
<b>Arterial Blood Gas</b>					
pН	7.33 (7.19-7.39)	7.30 (7.22-7.39)	7.37 (7.2-7.44)	7.35 (7.22-7.42)	7.18 (6.9-7.39)
PaCO2, mmHg	44 (33-51)	38 (33-51)	47 (34-56)	38 (33-51)	51 (45-59)
Bicarbonate, mmol/L	21 (17-24)	20 (17-23)	22 (17-26)	21 (18-24)	17 (11-27)
Hemoglobin, g/dL	10.3 (9.6-11.0)	10.0 (10.0-11.0)	10.6 (9.0-11.5)	10.0 (9.6-12.0)	10.6 (9.0-11.0)
Lactate, mmol/L	1.6 (1.0-3.0)	1.7 (1.2-3.4)	1.4 (0.9-2.6)	1.6 (0.9-3.0)	2 (1.0-7.9)
Lung mechanics					
PIP, cmH <sub>2</sub> O	28 (24-32)	27 (22-30)	29 (25-33)	25 (23-28)*	33 (32-35)
Pplat	20 (16-30)	18 (15-20)*	26 (19-30)	18 (15-22)*	30 (28-30)
PEEP, cmH <sub>2</sub> O	7 (6-11)	7 (5-10)	8 (7-12)	7 (6-11)	10 (7-12)
Paw	12.7 (11.0-16.4)	11.5 (10.0-16.0)	14.1 (11.6-17.5)	12.2 (10.0-16.3)	16 (12.1-18.3)
V <sub>T</sub> , ml/kg	7 (6-8)	7.0 (6.5-8.0)	6.5 (6.0-7.5)	7 (6-8)	7 (6-9)
Prone Position	9 (30)	3 (21)	6 (38)	6 (26)	3 (43)
Prone duration, hours	48 (48-48)	96 (48-96)	48 (48-48)	48 (48-48)	48 (48-96)
Neuromuscular	13 (43)	4 (29)	9 (56)	8 (35)	5 (71)
blocker					

blocker

Data are n (%) or median (IQR); \*p<0.05 using Fisher's exact test or Mann-Whitney U test. Abbreviations: FiO<sub>2</sub>: Fraction of inspired oxygen; PaO<sub>2</sub>: Arterial oxygen partial pressure; PaO<sub>2</sub>/FIO<sub>2</sub>: PaO<sub>2</sub> to FiO<sub>2</sub> ratio; P(A-a) O<sub>2</sub>: Alveolar–arterial oxygen gradient; PEEP: Positive end-expiratory pressure; PaCO<sub>2</sub>: Partial pressure of carbon dioxide; PIP: Peak inspiratory pressure; Vt/Kg: Tidal volume per kilogram; Pplat: plateau pressure; Paw: mean airway pressure; C-ARDS, Coronavirus associated acute respiratory distress syndrome; PARDS: Pediatric Acute Respiratory Distress Syndrome; C-PARDS, PARDS associated with COVID-19 pneumonia; MIS-PARDS, PARDS associated with multisystem inflammatory syndrome in children

Figure. 1. Study patient flow diagram.




(PARDS: Pediatric Acute Respiratory Distress Syndrome; C-PARDS, PARDS associated with COVID-19 pneumonia; MIS-PARDS, PARDS associated with multisystem inflammatory syndrome in children)


Figure 2. Boxplot graph of calculated parameters of lung mechanics of Children with PARDS associated with COVID-19, according to the clinical phenotypes and outcome. (A) The resistive component of work of breathing (Peak Inspiratory Pressure minus Plateau Pressure subtraction, [PIP-Pplat]); (B) the viscoelastic component of the work of breathing (Driving Pressure, DP); (C) compliance of the respiratory system  $(C_{RS})$ .

(PARDS: Pediatric Acute Respiratory Distress Syndrome; C-PARDS, PARDS associated with COVID-19 pneumonia; MIS-PARDS, PARDS associated with multisystem inflammatory syndrome in children)


A



В







# Supplementary files

# Table S1. Case definitions for phenotypes according to diagnostics tests available.

C-PARDS, pediatric acute respiratory syndrome associated to COVID-19 infection; MIS-PARDS, pediatric acute respiratory syndrome associated to multisystem inflammatory syndrome; rt-PCR, reverse transcription-polymerase chain reaction; MIS-C, multisystem inflammatory syndrome in children. \* epidemiologic contact.

	COVID-19 rt-PCR	MIS-C criteria	COVID-19 lgM	COVID-19 IgG
CDADDC	(+)	(-)	N/A	N/A
C-PARDS	(-)	(-)	(+)	(-)
	(-)	(+)	(-)	(-)*
MIS-PARDS	(+)	(+)	(-)	(+)
	(-)	(+)	(+)	(+)

Table S2. Echocardiogram findings in C-PARDS and MIS-PARDS phenotypes.

C-PARDS, pediatric acute respiratory syndrome associated to COVID-19 infection; MIS-PARDS, pediatric acute respiratory syndrome associated to multisystem inflammatory syndrome; LV, left ventricular.

	All	MIS-PARDS	C-PARDS
	n = 30	n = 14	n = 16
<b>Abnormal Coronaries</b>	2	2	0
LV Dysfunction	4	4	1
EF < 40%	0	0	0
No Echocardiogram	10	1	9

Figure S1. Receiver operator curve analysis for driving pressure and mortality.

Area under the ROC curve was 0.91 (95% CI 0.81-1.00), and the best cut point was 15 cmH<sub>2</sub>O (100% sensitivity and 87% specificity).

